Thyroid News

Older adults with hypothyroidism are 26% more likely to die of any cause when compared with euthyroid older adults, although secondary analyses suggest hypothyroidism is not associated with cardiovascular mortality, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Endocrine Today has compiled a list of recent FDA news stories relating to endocrine practice. Drugs under consideration included those for thyroid eye disease, diabetes, hypertriglyceridemia, Prader-Willi syndrome and nonalcoholic steatohepatitis.

Each month Endocrine Today reporters ask leading endocrinologists and diabetes educators about their resesarch and practices. Some of our recent Q&As are below.

Adults with inadequately controlled hypoparathyroidism reported substantial symptoms related to the disease and health-related quality of life, with the effect compared with other severe, chronic diseases, according to findings published in Clinical Endocrinology.

CHICAGO — There are many targeted agents being tested in the neoadjuvant setting for thyroid cancer, however, it is important to understand the appropriate setting for use in this population of patients, according to a speaker at the Annual Meeting of the American Thyroid Association.

Adults who do not display symptoms of thyroid dysfunction should not be screened for such conditions, according to a recommendation statement from the Canadian Task Force on Preventive Health Care published in CMAJ.

The NIH selected five scientists as Lasker Clinical Research Scholars.

Older adults with subclinical hypothyroidism assigned 1 year of levothyroxine therapy experienced no adverse changes in any bone parameters compared with similar adults assigned placebo, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Endocrine Today has compiled a list of the top five news reports posted from the American Thyroid Association Annual Meeting, held from Oct. 30 to Nov. 3 in Chicago.

WASHINGTON — A class of endocrine-disrupting chemicals known as PFAS may work as an “environmental trigger” to drive multiple adverse endocrine health effects, including obesity, thyroid dysfunction and low bone mineral density, although researchers caution that more studies on potential associations are needed.